Detalhe da pesquisa
1.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
2.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
3.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
N Engl J Med
; 387(24): 2232-2244, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507686
4.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626253
5.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Hematol Oncol
; 42(3): e3274, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711253
6.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
7.
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Br J Haematol
; 203(5): 736-746, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287117
8.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
9.
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(18): 1235-1247, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37403937
10.
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.
J Oncol Pharm Pract
; 29(1): 45-51, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34816754
11.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175021
12.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 380(18): 1726-1737, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31042825
13.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood
; 136(22): 2513-2523, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32735641
14.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
15.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
16.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970288
17.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421178
18.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 96(2): 226-233, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125764
19.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
20.
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Br J Haematol
; 188(3): 404-412, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468521